Compare Incyte Corporation (INCY) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Ross Stores, Inc. — how do they compare? Incyte Corporation trades at $120.93 (market cap $24.54B), while Ross Stores, Inc. trades at $248.51 (market cap $80.78B). The key difference: Ross Stores, Inc. is far larger — about 3.3× Incyte Corporation's market cap, and Ross Stores, Inc. pays a 0.71% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | ROST | |
|---|---|---|
Market Cap | $24.54B | $80.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $255.23 |
52-Week Low | $81.61 | $144.67 |
Enterprise Value | $20.04B | $81.37B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
ROST trades at $250.45, down 1.72% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $259.00. The company has consistently beaten earnings estimates, with Q1 2026 EPS of $2.02 exceeding the $1.73 forecast. Strong fundamentals include a net income margin of 9.74% and ROE of 38.98%, supported by revenue growth to $21.13 billion in 2025 and recent expansion with 47 new stores opened in mid-2026.
The outlook remains positive given earnings momentum and store growth, but elevated valuation ratios like a P/E of 35.17 pose a risk if growth slows. Analyst sentiment is bullish with 64% buy ratings, though technical indicators show mixed signals with RSI near overbought levels. Investors should weigh robust profitability against high multiples in a competitive retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
